{"entity":{"id":"nct04892342","kind":"trial","name":"Study of ESG401 in Adults With Solid Tumors","aka":[],"tldr":"An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.","summary":"Study of ESG401 in Adults With Solid Tumors. ClinicalTrials.gov record last updated 2025-09-12: completed. Enrollment is actual at 156 participants. Primary completion is actual at 2025-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.","status":"completed","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04892342","url":"https://clinicaltrials.gov/study/NCT04892342"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["esg401"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2025-09-12: completed. Enrollment is actual at 156 participants. Primary completion is actual at 2025-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT04892342","phase":"1/2","setting":"Study of ESG401 in Adults With Solid Tumors","sponsor":"Shanghai Escugen Biotechnology Co., Ltd","started":"2021-09-14","startedType":"actual","enrolled":156,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04892342/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"esg401","kind":"drug","name":"ESG401","route":"/drugs/esg401/"}]}}